Melanoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardMelanoma & SkinMelanomaSCE Medical Oncology

After complete resection of stage IIIB cutaneous melanoma, molecular testing shows BRAF V600E. The patient asks specifically about a molecularly targeted adjuvant option available through NICE. Which regimen fits that request?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Dabrafenib plus trametinib for twelve months

Explanation lettering: D = shown as A · C = shown as B · E = shown as C · B = shown as D · A = shown as E

A is correct. NICE TA544 recommends dabrafenib with trametinib after resection of stage III BRAF V600-mutant melanoma; the COMBI-AD course is 12 months. Encorafenib-binimetinib and vemurafenib-cobimetinib are established combinations in advanced disease but are not the NICE-appraised adjuvant regimen. BRAF- or MEK-inhibitor monotherapy is not the evidence-based adjuvant schedule. Anti-PD-1 therapy is another valid adjuvant class, but the stem asks specifically for the molecularly targeted option, avoiding the false claim that one commissioned class is universally preferred over the other.

Reference: NICE TA544 adjuvant dabrafenib with trametinib recommendations: https://www.nice.org.uk/guidance/ta544/chapter/1-Recommendations